Combined treatments in obsessive-compulsive disorder: Current knowledge and future prospects;L'Integrazione dei trattamenti nel disturbo ossessivo-compulsivo: Conoscenze attuali e prospettive future

Rivista di Psichiatria

Volumn 47, Issue 4, 2012, Pages 255-268

  Albert, Umberto ^a   Barbaro, Francesca ^a   Aguglia, Andrea ^a   Maina, Giuseppe ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CBT; Combined treatment; OCD; Pharmacological treatment; Sequential treatment; SRI

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

CHILD PSYCHIATRY; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEPRESSION; HUMAN; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; OBSESSIVE-COMPULSIVE DISORDER;

EID: 84866757633     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997; 58 suppl 12: 7-10. (Pubitemid 27516504)
2. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53-63.
3. AAVV. Consensus Conference (a cura di P. Pancheri). Linee guida per il trattamento psicofarmacologico del disturbo ossessivocompulsivo. Riv Psichiatr 1997; 32: 174-87.
4. March J, Frances A, Carpenter D, Kahn D (eds). The Expert Consensus Guideline Series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58: suppl 4.
5. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-96. (Pubitemid 41578819)
6. National Institute for Health and Clinical Excellence. Obsessive- compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. National Clinical Practice Guideline Number 31. London: NICE, 2006.
7. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, Virginia: American Psychiatric Association, 2007.
8. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive-compulsive disorder: a meta-analysis. Psychopharmacol 1998; 136: 205-16. (Pubitemid 28143169)
9. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004; 24: 1011-30. (Pubitemid 40247306)
10. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive compulsive rituals: I. Br J Psychiatry 1980; 136: 1-25. (Pubitemid 10175757)
11. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure, and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152: 522-34.
12. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5: 17-20.
13. Foa EB, Kozac MJ, Steketee GS, McCarthy PR. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. Br J Clin Psychol 1992; 31: 279-92.
14. Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 1998; 35: 71-8. (Pubitemid 28368353)
15. van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R. Cognitive and behavioural therapies alone versus in combination with fluvoxamina in the treatment of obsessive-compulsive disorder. J Nerv Ment Dis 1998; 186: 492-9. (Pubitemid 28378025)
16. O'Connor K, Todorov C, Robillard S, Borgeat F, Brault M. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry 1999; 44: 64-71. (Pubitemid 29146429)
17. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized placebo-controlled trial of exposure and ritual prevention, clomipramine and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 151-61. (Pubitemid 40095685)
18. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavioural therapy, sertraline and their combination for children and adolescents for obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292: 1969-76.
19. March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behaviour therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007; 61: 344-7. (Pubitemid 46108694)
20. Garcia AM, Sapyta JJ, Moore PS, et al. Predictors and Moderators of Treatment Outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry 2010; 49: 1024-33.
21. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283: 2529-36. (Pubitemid 30324195)
22. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry 2005; 66: 28-32. (Pubitemid 40637723)
23. Otto MW, Smits JA, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice 2005; 12: 72-86. (Pubitemid 40309355)
24. Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry 2007; 7: 18.
25. O'Sullivan G, Noshirvani H, Marks I, Monteiro W, Lelliott P. Six-year follow-up after exposure and clomipramine therapy for obsessive-compulsive disorder. J Clin Psychiatry 1991; 52: 150-5.
26. Cottraux J, Mollard E, Bouvard M, Marks I. Exposure therapy, fluvoxamine, or combination treatment of obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 1993; 49: 63-75. (Pubitemid 23329247)
27. Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums 2003; 8: 363-71.
28. Kordon A, Kahl KG, Brooks A, Voderholzer U, Rasche-Rauchle H, Hohagen F. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci 2005; 255: 48-50. (Pubitemid 40558105)
29. Rufer M, Hand I, Alsleben H, et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioural therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 2005; 255: 121-8. (Pubitemid 40575663)
30. van Oppen P, van Balkom AJLM, de Haan E, van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 2005; 66: 1415-22.
31. Maina G, Albert U, Pessina E, Salvi V, Bogetto F. Antipsychotics in obsessive-compulsive disorder. Curr Psychiatry Rev 2005; 1: 292-301.
32. Maina G, Albert U, Salvi V, Bogetto F. A review of current strategies for treatment resistant obsessive-compulsive disorder. Curr Drug Ther 2008; 3: 126-42.
33. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-32. (Pubitemid 43989810)
34. Tenneij NH, van Megen HJ, Denys DA, Westenberg HG. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 2005; 66: 1169-75. (Pubitemid 41442285)
35. Biondi M, Picardi A. Increased maintenance of obsessive-compulsive disorder remission after integrated serotonergic treatment and cognitive psychotherapy compared with medication alone. Psychother Psychosom 2005; 74: 123-8. (Pubitemid 40470266)
36. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999; 60: 584-90. (Pubitemid 29451554)
37. Kampman M, Keijsers GP, Hoogduin CA, Verbraak MJ. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand 2002; 106: 314-9.
38. Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry 2004; 65: 922-31.
39. de Haan E, van Oppen P, van Balkom A, Spinhoven P, Hoogduin KA, Van Dyck R. Prediction of outcome and early vs late improvement in OCD patients terated with cognitive-behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 1997; 96: 354-61. (Pubitemid 27496016)
40. Albert U, Maina G, Forner F, Bogetto F. Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs. Eur Neuropsychopharmacol 2003; 13 (suppl 4): S357.
41. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponder to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry 2007; 68: 1552-6. (Pubitemid 350073404)
42. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmachoterapy in obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 621-30. (Pubitemid 351705340)
43. Maher MJ, Hupper JD, Chen H, et al. Moderators and predictors of response to cognitive-behavioral thearapy augmentation of pharmacotherapy in obsessive-compulsive disorder. Psychol Med 2010; 40: 2013-23.
44. Anand N, Sudhir PM, Math SB, Thennarasu K, Reddy YCJ. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J Anxiety Disord 2011; 25: 939-45.
45. Storch EA, Bagner DM, Geffken GR, Adkins JW, Murphy TK, Goodman WK. Sequential cognitive-behavioral therapy for children with obsessive-compulsive disorder with an inadequate medication response: a case series of five patients. Depress Anxiety 2007; 24: 375-81. (Pubitemid 47606145)
46. O'Connor K, Aardema F, Robillard S, et al. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr Scand 2006; 113: 408-19.
47. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835-8. (Pubitemid 47488217)
48. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 335-41. (Pubitemid 351704489)
49. Chasson GS, Buhlmann U, Tolin DF, et al. Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010; 48: 675-9.
50. Storch EA, Murphy TK, Goodman WK, et al. A preliminary Study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2010; 68: 1073-6.
51. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22: 230-7. (Pubitemid 46801947)
52. Storch EA, Larson MJ, Muroff J, et al. Predictors of functional impairment in pediatric obsessive-compulsive disorder. J Anxiety Disord 2010; 24: 275-83.
53. Albert U, Maina G, Saracco P, Bogetto F. L'intevento psicoeducazionale multifamigliare (IPM) nel disturbo ossessivocompulsivo: uno studio pilota. Epidemiol Psichiatr Soc 2006; 15: 71-6.
54. Maina G, Saracco P, Albert U. Family-focused treatments for OCD. Clin Neuropsychiatry 2006; 3: 382-90.
55. Albert U, Salvi V, Saracco P, Bogetto F, Maina G. Health-related qualitiy of life in first-degree relatives of patients with obsessive-compulsive disorder. Psychiatr Serv 2007; 58: 970-6. (Pubitemid 47122876)
56. Albert U, Maina G, Bogetto F. Efficacy of multifamily psychoeducational intervention for family members of patients with obsessive-compulsive disorder. 6th International Congress of Cognitive Psychotheapy, Roma, June 19-22. Psicoterapia Cognitiva e Comportamentale 2008; 14: 13.
57. Albert U, Maina G, Bogetto F. Health-related quality of life in obsessive-compulsive disorder subjects and their relatives. In: Preedy VR, Watson RR (eds). Handbook of Disease Burdens and Quality of Life Measures. Milano: Springer, 2009.